The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma

Huang, Yen-HsiangYen-HsiangHuangHsu, Kuo-HsuanKuo-HsuanHsuChin, Chun-ShihChun-ShihChinTseng, Jeng-SenJeng-SenTsengYang, Tsung-YingTsung-YingYangChen, Kun-ChiehKun-ChiehChenKANG-YI SUSUNG-LIANG YUChen, Jeremy J WJeremy J WChenChang, Gee-ChenGee-ChenChang2022-05-122022-05-122022-041598-29982005-9256https://scholars.lib.ntu.edu.tw/handle/123456789/610527The aim of this study was to investigate the efficacy of various epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) plus bevacizumab in advanced EGFR-mutant lung adenocarcinoma patients.enAdenocarcinoma; Bevacizumab; ErbB receptors; Lung neoplasms; Tyrosine kinase inhibitor[SDGs]SDG3The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinomajournal article10.4143/crt.2021.671343529992-s2.0-85128493393https://api.elsevier.com/content/abstract/scopus_id/85128493393